2017/07/20 Journal Club

Enrichment of Human CCR6+ Regulatory T Cells with Superior Suppressive Activity in Oral Cancer.

(PubMed Link)

Yi-Hong's slides : 按我預覽或下載

2017/07/06 Journal Club

Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis.

<PubMed Link>

2017/06/22 Journal Club

mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation.

<PubMed Link>

Ming-Yu slides <按我預覽或下載>

2017/06/08 Journal Club

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

PubMed Link

Yun-Hsin slides 1 : 按我預覽或下載
Yun-Hsin slides 2_questions : 按我預覽或下載

2017/05/11 Journal Club

Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming

PubMed Link

Wei-Chan的slides <按我預覽或下載>

2017/04/27 Journal Club

PI3Kγ is a molecular switch that controls immune suppression.

(PubMed Link)

------------------------
Yi-Hongのslides  <按我預覽或下載>

2017/06/26 Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells 講者：許銘娟 博士 ( Dr.洪副實驗室博士後研究員 後來颱風取消)

2017/04/13 Journal Club

A Myc-dependent division timer complements a cell-death timer to regulate Tcell and B cell responses.

 (PubMed連結: 27820810)

___________________
SL的slides <按我預覽或下載>

Interesting paper found? Please deposit it here. Thank You.

If you found any interesting story and want to share with us, please drop the PubMed pmid or title of the paper by replying to the 'comments'. I will 'lift' it to the post content, assign an id and make link for the paper. Thank you.  Su-Fang

1. Identification of an Early Unipotent Neutrophil Progenitor with Pro-tumoral Activity in Mouse and Human Bone Marrow. (2018/08 Cell Rep) 
2. A New Perspective: Exploring Future Therapeutic Strategies For Cancer By Understanding The Dual Role Of B Lymphocytes In Tumor Immunity. (2018/ Int J Cancer)
   
3. IFNg-Dependent Tissue-Immune Homeostasis Is Co- opted in the Tumor Microenvironment (2017/06 Cell)
4. Interferon-g Drives Treg Fragility to Promote Anti- tumor Immunity (2017/06 Cell)
5. Targeting tumor-infiltrating Ly6G1 myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma (2017/12 Int J Cancer, NTUH)
6. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment (2018/01 J Immunol)
7. Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. (2017/12 J Pathol)
8. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient (2017/08 Cell )
9. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution (2017/11 Cell)
10. MHC-I Genotype Restricts the Oncogenic Mutational Landscape (2017/11 Cell)
11. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2017/12 Science)
12. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts (2017/12 Cell Reports)
13. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases (2017/12 Oncogene)
14. An immunogenic personal neoantigen vaccine for patients with melanoma (cancer vaccine 1/2, Catherine Wu group 28678778) 
15. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer (cancer vaccine 2/2, Ugur Sahin group 28678784)
16. An immune atlas of clear cell renal cell carcinoma (using CyTOF to detect TILs 28475899) 
17. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses (using scRNA-seq to detect TILs 28475900)
18. 麗蓉老師推薦 Effective combinatorial immunotherapy for castration-resistant prostate cancer (Ronald A. DePinho 且有 CyTOF) (28321130) (Erratum)
19. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. (11323675)
20. XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. (25893296)
21. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. (27265504)
22. Indomethacin Treatment of Mice with Premalignant Oral Lesions Sustains Cytokine Production and Slows Progression to Cancer. (27713748) 
23. Metastasis: Pathways of parallel progression (27974802)(27974799)(27974798).

2017/03/30 Journal Club

Mitochondrial function provides instructive signals for activation-induced B-cell fates.

(PubMed連結: 25857523)

 Ming-YuのSlides <按我預覽或下載>

2017/03/16 Journal Club

Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche.

(PubMed 連結)

---------------

Yun-Hsin Slide <按我預覽或下載>

2017/03/09 Journal Club

The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory.

(PubMed連結)
-------------------------------
Yi-Chen slide 按我預覽或下載
Yi-Chen 補充說明slide 按我預覽或下載

2017/02/23 Journal Club paper

Succinate is an inflammatory signal that induces IL-1β through HIF-1α.

<PubMed連結>

Wei-Chanの slide <按我預覽或下載>

--------------------------------------------------------
2014/06/20  咦, 有PubPeer alert呦...
Christos Chinopoulos | Jun 20 2014 05:48 EST

Could it be that LPS-induced succinate over-production is due to itaconate formation? LPS induces Irg1, a gene coding for cis-aconitate decarboxylase, specifically expressed in cells of macrophage lineage Proc Natl Acad Sci U S A. 2013 May 7;110(19):7820-5. doi: 10.1073/pnas.1218599110, yielding itaconate.  Itaconate is preferentially used by succinyl CoA ligase forming itaconyl CoA, thus generating an accumulation of succinate when the ligase operates towards succinyl CoA formation ADLER J, WANG SF, & Lardy HA (1957) The metabolism of itaconic acid by liver mitochondria. J. Biol. Chem, 229, 865-879, and WANG SF, ADLER J, & Lardy HA (1961) The pathway of itaconate metabolism by liver mitochondria. J. Biol. Chem, 236, 26-30. http://www.ncbi.nlm.nih.gov/pubmed/23535595#cm23535595_4939

--------------------------------------------------
2017/02/23 奕宏問了一個好問題, 抱歉, 我回來想想我當場的解釋並不正確, 現在重來一次! Orz...

Suppl Fig 15

奕宏問說, 既然IL1B是HIF1A(a transcription factor)的下游, 何以兩者的表現量未呈正相關?

我原先回答說transcript regulation level(IL1B)和protein regulation level (HIF1A)不同, 不用這樣子一起比。但是， 仔細看著它們， 既然細胞是一樣的， 不管受什麼level調節，兩者應該要同上同下才對，因為它們的context是相同的。

因此，剩下的唯一可能應是使用diethylsuccinate(DS)和butylmalonate(BM)所造成的差異。例如，BM除了induce HIF1A stabilization以外，還有stabilize其它IL1B之上游分子，而那些因子在DS那一組並未出現。如此便可解釋為何HIF1A和IL1B在兩種藥處理下，蛋白量並未成正相關。 How do you like this idea, Yi-Hong? 😀